Lumida
/PBH
⌘K
Prestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc

PBH
$46.95USD-0.82%-0.39 today

MARKET CAP

2.2B

P/E (TTM)

12.0x

FWD P/E

DAY RANGE

$46 – $48

52W RANGE

$43
$71

AI Summary

Stalk
Sell NowMedium

The breakdown below the $50.60–$49.70 support zone on elevated volume under Stage 4 decline confirms a medium-term bearish bias. Price sits below the 9/21 EMAs and 50 SMA in an extended downtrend into extreme oversold territory. With no stabilizing reversal structures, selling into any rally toward the broken support or EMAs is advised immediately.

  • Q1 revenue $266M (+6.5% YoY) and record $83.7M free cash flow
  • Breathe Right and Lacorium acquisitions to add ~$190M revenue this year
  • Full-year revenue fell 4.5% YoY, driven by eye care supply issues
Full analysis →
STATEMENT·Income statement
USD · GAAP
METRICFY 2022FY 2023FY 2024FY 2025FY 2026TREND
Sales, Adj.$1.1B$1.1B$1.1B$1.1B$1.1B
YoY %+15.2%+3.8%-0.2%+1.1%-4.3%
P / Sales2.5x2.8x3.2x3.8x2.7x
EV / Sales4.4x4.4x4.6x5.1x4.1x
Gross Profit, Adj.$620.6M$625.3M$624.4M$634.5M$595.6M
YoY %+13.4%+0.7%-0.1%+1.6%-6.1%
Margin %57.1%55.4%55.5%55.8%54.7%
EV / Gross Profit7.7x8.0x8.3x9.1x7.4x
EBITDA, Adj.$363.1M$380.4M$373.1M$379.4M$340.7M
YoY %+10.0%+4.8%-1.9%+1.7%-10.2%
Margin %33.4%33.7%33.2%33.3%31.3%
EV / EBITDA13.1x13.1x14.0x15.2x13.0x
EBIT$329.9M$-22.4M$342.4M$336.8M$309.4M
YoY %+10.9%-106.8%+1627.7%-1.7%-8.1%
Margin %30.4%-2.0%30.4%29.6%28.4%
EV / EBIT14.4x-221.8x15.2x17.1x14.3x
Net Income$205.4M$-82.3M$209.3M$214.6M$190.3M
YoY %+24.7%-140.1%+354.3%+2.5%-11.3%
Net Margin18.9%-7.3%18.6%18.9%17.5%
EPS (GAAP)$4.04-$1.65$4.17$4.29$3.91
YoY %+24.3%-140.8%+352.7%+2.9%-8.9%